Resolvins RvD1 and 17(R)-RvD1 alleviate signs of inflammation in a rat model of endometriosis

Dmitrieva, Natalia O.; Suess, Gregory; Shirley, Russell

doi:10.1016/j.fertnstert.2014.06.046

Cited by 20 publications

(21 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo , RVD1, RVD2 and/or MaR1 have been shown to suppress pro-inflammatory cytokine production during multiple inflammatory conditions with protective consequences, including experimental uveitis, 10 hepatic ischemia/reperfusion injury, 11 peritonitis, 12 periodontitis, 13 acute lung injury, 14–18 colitis, 19,20 endometriosis 21 and endotoxic shock. 22 Resolvins have also been reported to abet caspase-dependent neutrophil apoptosis, 14,23 to augment efferocytosis 24,25 and to promote the de novo generation of regulatory T cells.…”

Section: Introductionmentioning

confidence: 99%

Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes

Lamont

et al. 2016

Innate Immun

View full text Add to dashboard Cite

Pro-resolving, docosahexaenoic acid-derived mediators have recently emerged as important potential therapeutic agents for the amelioration of complications arising from inflammation, such as vascular disease, asthma, acute lung injury and colitis. While resolvin D1 (RVD1), resolvin D2 (RVD2) and maresin 1 (MaR1) are established pro-resolvins, their mechanisms of action remain unclear. Here we show that, in LPS-stimulated primary human monocytes, RVD1, RVD2 and MaR1 each suppress the release of pro-inflammatory cytokines (TNF, IL-1β, IL-8) and the innate/adaptive bridging cytokine, IL-12 p40, while simultaneously augmenting the production of the anti-inflammatory cytokine, IL-10. Such resolving activity is accompanied by the increased phosphorylation (enhanced anti-inflammatory state) of glycogen synthase kinase 3β (GSK3β) along with increased phosphorylation (activation) of Akt, SGK1 and CREB but not MAPK-related molecules. Gain and loss of function experiments confirm a key role for GSK3β and CREB in the anti-inflammatory actions of resolvins. These results suggest that induction of the GSK3β anti-inflammatory axis is a common mechanism of action for RVD1, RVD2 and MaR1.

show abstract

Section: Introductionmentioning

confidence: 99%

Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes

Lamont

et al. 2016

Innate Immun

View full text Add to dashboard Cite

show abstract

“…Intake of food with a high content of O-PUFA has been shown to have an anti-inflammatory effect in conditions such as atherosclerosis [10]. Importantly, it has been shown that O-PUFAs can serve as substrates for formation of a wide range of mediators implicated in resolution of inflammation [11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

“…In a rat model of endometriosis, O-PUFA reduced lesion size and local prostaglandin and cytokine production [15]. Administration of D-series resolvins (DHA metabolites) also reduced vaginal hyperalgesia [14]. In an endometriosis model using Fat-1 mice, in which Omega-6 can be converted to O-PUFA, the number of induced lesions were significantly less in Fat-1 mice compared to controls [13] and inflammatory mediators such as IL-6 and Cox-2 levels were reduced [12].…”

Section: Introductionmentioning

confidence: 99%

A two-arm parallel double-blind randomised controlled pilot trial of the efficacy of Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis-associated pain (PurFECT1)

et al. 2020

View full text Add to dashboard Cite

BackgroundEndometriosis is defined by the presence of endometrial-like tissue (lesions) outside the uterus, commonly on the pelvic peritoneum. It affects 6-10% of women and is associated with debilitating pelvic pain. Current management options are often unsatisfactory. Omega-3 polyunsaturated fatty acids (O-PUFA) have the potential to reduce the painful symptoms associated with endometriosis, reduce lesion size, preserve the patient's ability to conceive, and have minimal side effects. We performed a two-arm, parallel double-blinded randomised controlled trial to inform the planning of a future multicentre randomised controlled trial to evaluate the efficacy of O-PUFA for endometriosis-associated pain. ObjectivesThe primary objectives of the trial were to assess recruitment and retention rates. The secondary objectives were to determine the acceptability to women of the proposed methods of recruitment, randomisation, treatments and questionnaires, to estimate the variability in the proposed primary endpoints to inform the sample size calculation and to refine the research methodology for the future definitive trial.

show abstract

“…RvD1 produced beneficial effects in multiple inflammatory murine models. Examples include the following: (i) reducing functional and morphological kidney injury following bilateral ischemia/reperfusion injury (Marcheselli et al , ; Duffield et al , ), (ii) decreasing adipose tissue macrophage accumulation to improve insulin sensitivity in obese‐diabetic mice (Hellmann et al , ), (iii) attenuating arthritis severity and enhancing collagen repair in arthritic mice (Norling et al , ), (iv) alleviating inflammation associated with endometriosis (Dmitrieva et al , ), (v) reducing mucosal inflammation following acute lung injury (Eickmeier et al , ), and alleviating allergic airway responses (Rogerio et al , ) and chronic emphysema (Hsiao et al , ). RvD2 appears to be a potent regulator of leukocytes, controlling microbial sepsis (Spite et al , ) and responding to E. coli peritonitis (Gao et al , ).…”

Section: Lipid Mediators Involved In Inflammationmentioning

confidence: 99%

Regulation of inflammation by lipid mediators in oral diseases

Sommakia

Baker

2016

Oral Diseases

View full text Add to dashboard Cite

Lipid mediators (LM) of inflammation are a class of compounds derived from ω-3 and ω-6 fatty acids that play a wide role in modulating inflammatory responses. Some LM possess pro-inflammatory properties, while others possess pro-resolving characteristics, and the class switch from pro-inflammatory to pro-resolving is crucial for tissue homeostasis. In this article, we review the major classes of LM, focusing on their biosynthesis and signaling pathways, and their role in systemic and, especially, oral health and disease. We discuss the detection of these LM in various body fluids, focusing on diagnostic and therapeutic applications. We also present data showing gender-related differences in salivary LM levels in healthy controls, leading to a hypothesis on the etiology of inflammatory diseases, particularly, Sjögren’s Syndrome. We conclude by enumerating open areas of research where further investigation of LM is likely to result in therapeutic and diagnostic advances.

show abstract

Resolvins RvD1 and 17(R)-RvD1 alleviate signs of inflammation in a rat model of endometriosis

Cited by 20 publications

References 69 publications

Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes

Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes

A two-arm parallel double-blind randomised controlled pilot trial of the efficacy of Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis-associated pain (PurFECT1)

Regulation of inflammation by lipid mediators in oral diseases

Contact Info

Product

Resources

About